Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

NOS2 inhibitor 1400W Induces Autophagic Flux and Influences Extracellular Vesicle Profile in Human Glioblastoma U87MG Cell Line.

Palumbo P, Lombardi F, Augello FR, Giusti I, Luzzi S, Dolo V, Cifone MG, Cinque B.

Int J Mol Sci. 2019 Jun 20;20(12). pii: E3010. doi: 10.3390/ijms20123010.

2.

Short exposure to tranexamic acid does not affect, in vitro, the viability of human chondrocytes.

Goderecci R, Giusti I, Necozione S, Cinque B, D'Ascenzo S, Dolo V, Calvisi V.

Eur J Med Res. 2019 Feb 22;24(1):15. doi: 10.1186/s40001-019-0373-x.

3.

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MÁ, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK.

J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. eCollection 2018.

4.

Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior.

Giusti I, Di Francesco M, D'Ascenzo S, Palmerini MG, Macchiarelli G, Carta G, Dolo V.

Cancer Biol Ther. 2018 Aug 3;19(8):722-734. doi: 10.1080/15384047.2018.1451286. Epub 2018 Apr 25.

5.

Leukocyte depletion does not affect the in vitro healing ability of platelet rich plasma.

Giusti I, Di Francesco M, D'Ascenzo S, Palumbo P, Rughetti A, Dell'Orso L, Varasano PA, Pressanti GL, Dolo V.

Exp Ther Med. 2018 Apr;15(4):4029-4038. doi: 10.3892/etm.2018.5887. Epub 2018 Feb 22.

6.

CD18-mediated adhesion is required for the induction of a proinflammatory phenotype in lung epithelial cells by mononuclear cell-derived extracellular vesicles.

Neri T, Scalise V, Passalacqua I, Giusti I, Lombardi S, Balia C, D'Alessandro D, Berrettini S, Pedrinelli R, Paggiaro P, Dolo V, Celi A.

Exp Cell Res. 2018 Apr 1;365(1):78-84. doi: 10.1016/j.yexcr.2018.02.023. Epub 2018 Feb 21.

PMID:
29476835
7.

Extracellular vesicle-packaged miRNA release after short-term exposure to particulate matter is associated with increased coagulation.

Pergoli L, Cantone L, Favero C, Angelici L, Iodice S, Pinatel E, Hoxha M, Dioni L, Letizia M, Albetti B, Tarantini L, Rota F, Bertazzi PA, Tirelli AS, Dolo V, Cattaneo A, Vigna L, Battaglia C, Carugno M, Bonzini M, Pesatori AC, Bollati V.

Part Fibre Toxicol. 2017 Aug 24;14(1):32. doi: 10.1186/s12989-017-0214-4.

8.

Extracellular Vesicle-Shuttled mRNA in Mesenchymal Stem Cell Communication.

Ragni E, Banfi F, Barilani M, Cherubini A, Parazzi V, Larghi P, Dolo V, Bollati V, Lazzari L.

Stem Cells. 2017 Apr;35(4):1093-1105. doi: 10.1002/stem.2557. Epub 2017 Feb 5.

9.

From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis.

Giusti I, Delle Monache S, Di Francesco M, Sanità P, D'Ascenzo S, Gravina GL, Festuccia C, Dolo V.

Tumour Biol. 2016 Sep;37(9):12743-12753. Epub 2016 Jul 22.

PMID:
27448307
10.

Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications.

Giusti I, Di Francesco M, Dolo V.

Curr Cancer Drug Targets. 2017;17(3):221-235. doi: 10.2174/1568009616666160813182959. Review.

PMID:
27528364
11.

p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma.

Cutilli T, Leocata P, Dolo V, Altobelli E.

Oncol Lett. 2016 Aug;12(2):1046-1050. Epub 2016 Jun 16.

12.

The human ovarian cancer cell line CABA I: A peculiar genetic evolution.

Giusti I, Cervelli C, D'Ascenzo S, Di Francesco M, Ligas C, D'Alessandro E, Papola F, Dolo V.

Int J Mol Med. 2016 Apr;37(4):879-88. doi: 10.3892/ijmm.2016.2501. Epub 2016 Feb 25.

13.

Association between p53 status, human papillomavirus infection, and overall survival in advanced oral cancer after resection and combination systemic treatment.

Cutilli T, Leocata P, Dolo V, Altobelli E.

Br J Oral Maxillofac Surg. 2016 Feb;54(2):198-202. doi: 10.1016/j.bjoms.2015.11.011. Epub 2015 Dec 6.

PMID:
26669794
14.

Time-dependent release of extracellular vesicle subpopulations in tumor CABA I cells.

Giusti I, Di Francesco M, Cantone L, D'Ascenzo S, Bollati V, Carta G, Dolo V.

Oncol Rep. 2015 Nov;34(5):2752-9. doi: 10.3892/or.2015.4199. Epub 2015 Aug 12.

PMID:
26323210
15.

Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro.

Giusti I, D'Ascenzo S, Mancò A, Di Stefano G, Di Francesco M, Rughetti A, Dal Mas A, Properzi G, Calvisi V, Dolo V.

Biomed Res Int. 2014;2014:630870. doi: 10.1155/2014/630870. Epub 2014 Jul 23.

16.

Extracellular vesicles in prostate cancer: new future clinical strategies?

Giusti I, Dolo V.

Biomed Res Int. 2014;2014:561571. doi: 10.1155/2014/561571. Epub 2014 Feb 23. Review.

17.

Topical application of platelet supernatant gel in the management of radiotherapy-induced mucositis: a case report.

Di Staso M, Rughetti A, Dell'Orso L, Marampon F, La Verghetta ME, Parente S, Gravina GL, Aielli F, Dolo V, Ruggieri V, Franzese P, Bonfili P, Tombolini V, Di Cesare E.

Blood Transfus. 2014 Jan;12(1):107-10. doi: 10.2450/2013.0104-13. Epub 2013 Oct 22. No abstract available.

18.

Evaluation of p53 protein as a prognostic factor for oral cancer surgery.

Cutilli T, Leocata P, Dolo V, Altobelli E.

Br J Oral Maxillofac Surg. 2013 Dec;51(8):922-7. doi: 10.1016/j.bjoms.2013.05.150. Epub 2013 Jun 20.

PMID:
23791033
19.

Microvesicles as potential ovarian cancer biomarkers.

Giusti I, D'Ascenzo S, Dolo V.

Biomed Res Int. 2013;2013:703048. doi: 10.1155/2013/703048. Epub 2013 Jan 8. Review.

20.

The effects of platelet gel-released supernatant on human fibroblasts.

Giusti I, Rughetti A, D'Ascenzo S, Di Stefano G, Nanni MR, Millimaggi D, Dell'orso L, Dolo V.

Wound Repair Regen. 2013 Mar-Apr;21(2):300-8. doi: 10.1111/wrr.12025. Epub 2013 Feb 25.

PMID:
23438188
21.

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.

Gravina GL, Ranieri G, Muzi P, Marampon F, Mancini A, Di Pasquale B, Di Clemente L, Dolo V, D'Alessandro AM, Festuccia C.

Oncol Rep. 2013 Mar;29(3):1189-95. doi: 10.3892/or.2012.2192. Epub 2012 Dec 18.

PMID:
23254386
22.

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.

Int J Oncol. 2012 Mar;40(3):711-20. doi: 10.3892/ijo.2011.1270. Epub 2011 Nov 23.

PMID:
22134754
23.

Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.

Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V.

Gynecol Oncol. 2010 Dec;119(3):557-63. doi: 10.1016/j.ygyno.2010.07.036. Epub 2010 Sep 9.

PMID:
20825984
24.

Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.

Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V.

Cancer Res. 2010 Aug 1;70(15):6150-60. doi: 10.1158/0008-5472.CAN-09-2758. Epub 2010 Jul 14.

25.

Vasculogenic mimicry of human ovarian cancer cells: role of CD147.

Millimaggi D, Mari M, D' Ascenzo S, Giusti I, Pavan A, Dolo V.

Int J Oncol. 2009 Dec;35(6):1423-8.

PMID:
19885565
26.

Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy.

Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, Spinelli GP, Pauselli S, Sale P, Dolo V, De Lorenzo F, Tomao F, Benedetti-Panici P, Frati L, Nuti M.

Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):647-58.

PMID:
19822081
27.

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.

Festuccia C, Gravina GL, Biordi L, D'Ascenzo S, Dolo V, Ficorella C, Ricevuto E, Tombolini V.

Prostate. 2009 Oct 1;69(14):1529-37. doi: 10.1002/pros.20995.

PMID:
19562712
28.

Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.

Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M.

Urology. 2009 Aug;74(2):452-7. doi: 10.1016/j.urology.2009.01.018. Epub 2009 Mar 13.

PMID:
19285710
29.

Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells.

Giusti I, Rughetti A, D'Ascenzo S, Millimaggi D, Pavan A, Dell'Orso L, Dolo V.

Transfusion. 2009 Apr;49(4):771-8. doi: 10.1111/j.1537-2995.2008.02033.x. Epub 2008 Dec 23.

PMID:
19170984
30.

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Endocr Relat Cancer. 2009 Jun;16(2):401-13. doi: 10.1677/ERC-08-0130. Epub 2009 Jan 19.

PMID:
19153211
31.

Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.

Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Ficorella C, Ricevuto E, Bologna M.

Prostate. 2009 Mar 1;69(4):337-45. doi: 10.1002/pros.20884.

PMID:
19016477
32.

Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells.

Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F.

Cancer Res. 2008 Aug 15;68(16):6541-9. doi: 10.1158/0008-5472.CAN-07-6763.

33.

Platelet gel-released supernatant modulates the angiogenic capability of human endothelial cells.

Rughetti A, Giusti I, D'Ascenzo S, Leocata P, Carta G, Pavan A, Dell'Orso L, Dolo V.

Blood Transfus. 2008 Jan;6(1):12-7.

34.

Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.

Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Int J Oncol. 2008 Aug;33(2):381-8.

PMID:
18636160
35.

Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles.

Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V.

Neoplasia. 2008 May;10(5):481-8.

36.

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.

Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M.

Prostate. 2008 Jun 15;68(9):965-74. doi: 10.1002/pros.20757.

PMID:
18361408
37.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
38.

Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.

Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Cerù MP, Bologna M.

Prostate. 2008 May 1;68(6):588-98. doi: 10.1002/pros.20708.

PMID:
18288684
39.

Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.

Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, Dolo V, Pavan A, Saccardi R, Tyndall A, Giacomelli R, Cerinic MM.

Arthritis Rheum. 2007 Jun;56(6):1994-2004.

40.

Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells.

Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V.

Neoplasia. 2007 Apr;9(4):349-57.

41.

Detrimental effects of anabolic steroids on human endothelial cells.

D'Ascenzo S, Millimaggi D, Di Massimo C, Saccani-Jotti G, Botrè F, Carta G, Tozzi-Ciancarelli MG, Pavan A, Dolo V.

Toxicol Lett. 2007 Mar 8;169(2):129-36. Epub 2007 Jan 3.

PMID:
17267145
42.

Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.

Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Int J Oncol. 2007 Jan;30(1):193-200.

PMID:
17143529
43.

Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways.

Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, Bernardini S.

Anticancer Drugs. 2006 Nov;17(10):1141-50.

PMID:
17075313
44.

Serum CA125 level modifications in women undergoing repeated IVF cycles.

Caserta D, Marci R, Tatone C, Dolo V, Di Roma E, Fazi A, Moscarini M.

Eur J Gynaecol Oncol. 2006;27(4):353-5.

PMID:
17009624
45.

Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.

Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, Dolo V.

Neoplasia. 2006 Feb;8(2):96-103.

46.

Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells.

Millimaggi D, Festuccia C, Angelucci A, D'Ascenzo S, Rucci N, Flati S, Bologna M, Teti A, Pavan A, Dolo V.

Int J Oncol. 2006 Apr;28(4):909-14.

PMID:
16525640
47.

Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.

Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V.

Biochem J. 2006 Apr 15;395(2):311-8.

48.

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

Endocr Relat Cancer. 2005 Dec;12(4):983-98.

PMID:
16322337
49.

Alterations of choline phospholipid metabolism in ovarian tumor progression.

Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F.

Cancer Res. 2005 Oct 15;65(20):9369-76.

50.

GnRH antagonist in IVF poor-responder patients: results of a randomized trial.

Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M.

Reprod Biomed Online. 2005 Aug;11(2):189-93.

PMID:
16168215

Supplemental Content

Support Center